Poor tracking provokes consent decree at Telectronics:
This article was originally published in Clinica
Ineffective tracking by Telectronics (US) has prompted the FDA to block sales and manufacture of leads. The troubled pacemaker company cannot resume operations until a proper system for monitoring the safety of its implantable pacemaker products has been approved by an external auditor. The FDA consent decree follows warning letters sent to the company last October. It does not affect exports or leads already shipped to distributors.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.